Dovato vs. Atripla

• Are Dovato and Atripla the Same Thing?
• What Are Possible Side Effects of Dovato?
• What Are Possible Side Effects of Atripla?
• What Is Dovato?
• What Is Atripla?
• What Drugs Interact with Dovato?
• What Drugs Interact with Atripla?
• How Should Dovato Be Taken?
• How Should Atripla Be Taken?

Dovato (inotuzumab ozogamicin) for injection and Atripla (gemtuzumab ozogamicin for injection) are monoclonal antibodies used to treat different types of leukemia.

Dovato is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Atripla is used to treat acute myeloid leukemia (AML). Atripla is usually given to people who are at least 60 years old and have a relapse of their disease and who cannot receive other cancer medications.

The brand name Atripla is discontinued, but generic versions may be available.

Dovato and Atripla are different types of monoclonal antibodies. Dovato is a CD22-directed monoclonal antibody and Atripla is a CD33-directed monoclonal antibody.

Side effects of Dovato and Atripla that are similar include fever, chills, nausea, vomiting, headache, diarrhea, and constipation.

Side effects of Dovato that are different from Atripla include low platelet counts (thrombocytopenia), low white blood cell counts (neutropenia, leukopenia), infection, anemia, fatigue, bleeding, febrile neutropenia, increased transaminases, abdominal pain, swelling and sores inside the mouth, increased gamma-glutamyltransferase, and too much bilirubin in the blood.

Side effects of Atripla that are different from Dovato include dizziness, anxiety, depression, sleep problems (insomnia), shortness of breath, high or low blood pressure, high blood sugar, and low blood oxygen.

Dovato may interact with drugs known to prolong the QT interval or induce Torsades de Pointes.

Atripla may interact with "live" vaccines, other chemotherapy treatments, antibiotics, antifungals, antidepressants, anti-malaria medicines, asthma inhalers, antipsychotic medicines, certain HIV/AIDS medicines, heart or blood pressure medicines, and medicines to prevent vomiting.

Common side effects of Dovato include:

• headache,
• diarrhea,
• nausea,
• insomnia,
• fatigue, and
• dizziness

Common side effects of Atripla include:

• dizziness,
• trouble sleeping,
• drowsiness,
• unusual dreams, and
• trouble concentrating.

Side effects may begin 1-2 days after starting Atripla and usually go away in 2-4 weeks. Other side effects of Atripla include:

• tiredness,
• headache,
• nausea,
• vomiting,
• gas,
• upset stomach,
• diarrhea, and
• skin discoloration (such as small spots/freckles, darkening of the palms of the hands/soles of the feet), and
• changes in the shape or location of body fat (especially in your arms, legs, face, neck, breasts, and waist).

Tell your doctor if you have serious side effects of Atripla including:

• unexplained weight loss,
• persistent muscle aches or weakness,
• joint pain,
• numbness or tingling of the hands/feet/arms/legs,
• severe tiredness,
• vision changes,
• severe or persistent headaches,
• signs of infection (such as fever, chills, trouble breathing, cough, non-healing skin sores),
• signs of an overactive thyroid (such as irritability, nervousness, heat intolerance, fast/pounding/irregular heartbeat, bulging eyes, unusual growth in the neck or thyroid known as a goiter), or
• signs of a certain nerve problem known as Guillain-Barre Syndrome (such as difficulty breathing/swallowing/moving your eyes, drooping face, paralysis, slurred speech).

Dovato (dolutegravir and lamivudine) is a combination of an integrase strand transfer inhibitor (INSTI) and a nucleoside analogue reverse transcriptase inhibitor (NRTI) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of Dovato.

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) is an antiviral medication that treats HIV, which causes acquired immunodeficiency syndrome (AIDS). Atripla is not a cure for HIV or AIDS.

Dovato may interact with other antiretroviral drugs for the treatment of HIV-1 infection, dofetilide, metformin, anticonvulsants, rifampin, St. John's wort, cation-containing antacids or laxatives, sucralfate, buffered medications, oral calcium and iron supplements (including multivitamins containing calcium or iron), and sorbitol.

Atripla (efavirenz, lamivudine and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor, and two nucleo(t)side reverse transcriptase inhibitors indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.

The dose of Dovato is one tablet taken orally once daily with or without food.

The adult dose of Atripla is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may improve the tolerability of nervous system symptoms.